Neuralink Approved for Second Human Brain Chip Implant

FDA grants Neuralink permission to proceed with a new method to address issues from the first trial.

Neuralink's first patient experienced significant thread retraction, affecting the implant's functionality.
The company plans to embed the device's wires deeper into the brain to prevent movement.
More than 1,000 quadriplegics have applied for the trial, but fewer than 100 meet the criteria.
Neuralink aims to implant its brain chips in 10 patients by the end of the year.
The FDA approval follows adjustments to the chip's algorithm to compensate for lost data.